|
|
|
|
Alto Neuroscience Inc (NYSE: ANRO) |
|
Price: $2.3500
$0.07 
3.070%
|
| Day's High:
| $2.35
| Week Perf:
| 2.84 %
|
| Day's Low: |
$ 2.20 |
30 Day Perf: |
-11.32 % |
| Volume (M): |
142 |
52 Wk High: |
$ 17.55 |
| Volume (M$): |
$ 333 |
52 Wk Avg: |
$7.66 |
| Open: |
$2.25 |
52 Wk Low: |
$1.60 |
|
|
| Market Capitalization (Millions $) |
58 |
| Shares
Outstanding (Millions) |
25 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-61 |
| Cash Flow (TTM) (Millions $) |
86 |
| Capital Exp. (TTM) (Millions $) |
2 |
Alto Neuroscience Inc
Company Address: 650 Castro Street, Suite 450 Mountain View 94041 CA
Company Phone Number: 200-0412 Stock Exchange / Ticker: NYSE ANRO
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Wed, Dec 11 2024 2:47 PM UTC
Alto Neuroscience: Progress Amidst Challenges at the 63rd Annual ACNP MeetingAlto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company dedicated to the development of innovative precision medicines for neuropsychiatric disorders, made significant waves at the 63rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held from Dece...
|
| Business Update
Published Wed, Sep 4 2024 12:47 PM UTC
Alto Neuroscience Unveils Revelatory Publication: Baseline Cognitive Performance Does Not Influence Antidepressant Efficacy Mountain View, Calif. In an era where the elucidation of neuropsychiatric maladies remains paramount, Alto Neuroscience, Inc., a company in the clinical-stage biopharmaceutical sphere, heralds a remarkable advancement with a newly peer-reviewed public...
|
| Stocks on the Move
Published Thu, Aug 15 2024 10:21 AM UTC
Is Palo Alto Networks the Best Cybersecurity Stock to Buy Now In today s sell-off of Alto Neuroscience Inc shares, investors are left questioning their choices and seeking alternative investment opportunities. The recent increase in cyberattacks globally has highlighted the urgent need for top-notch cybersecurity solutions, which has led many to consider Palo Alto Networks a...
|
| Business Update
Published Tue, Jul 16 2024 12:56 PM UTC
Mountain View, Calif. - Alto Neuroscience, a clinical-stage biopharmaceutical company dedicated to developing pioneering precision medicines for neuropsychiatric disorders, proudly announces the successful completion of patient enrollment in its Phase 2b study evaluating ALTO-100 in adults diagnosed with major depressive disorder (MDD). With topline results projected to be r...
|
| Business Update
Published Thu, Jun 20 2024 2:47 PM UTC
Alto Neuroscience Ventures into Phase 2 Study of ALTO-101: A Groundbreaking Treatment for Cognitive Impairment in Schizophrenia LOS ALTOS, Calif. - Alto Neuroscience, a leading biotech company, has recently launched a pivotal Phase 2 clinical trial for its groundbreaking drug, ALTO-101. This transdermal formula, a novel phosphodiesterase-4 (PDE4) inhibitor, seeks to address ...
|
| Per Share |
Current |
| Earnings (TTM) |
-2.5 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
3.51 $ |
| Cash |
6.85 $
|
| Book Value |
6.16 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-2.5 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
3.51 $ |
| Cash |
6.85 $
|
| Book Value |
6.16 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
16.64%